Phase II trial of MVI 816 in men with PSA-recurrent non-metastatic prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 23 Jun 2014
At a glance
- Drugs MVI 816 (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 29 Jan 2014 New trial record
- 13 Jan 2014 Madison Vaccines has closed an $US8 million Series A financing, the proceeds of which will partly go towards completion of this trial, according to a Madison Vaccines media release.